Unknown

Dataset Information

0

Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective.


ABSTRACT:

Background

In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing on the long-term nutritional status of CGMP-AA are lacking. This retrospective study evaluated the long-term impact of CGMP-AA over a mean of 29 months in 11 patients with a mean age at CGMP-AA onset of 28 years (range 15-43) [8 females; 2 hyperphenylalaninaemia (HPA), 3 mild PKU, 3 classical PKU and 3 late-diagnosed]. Outcome measures included metabolic control, anthropometry, body composition and biochemical parameters.

Results

CGMP-AA, providing 66% of protein equivalent intake from protein substitute, was associated with no significant change in blood Phe with CGMP-AA compared with baseline (562?±?289 µmol/L vs 628?±?317 µmol/L; p?=?0.065). In contrast, blood tyrosine significantly increased on CGMP-AA (52.0?±?19.2 ?mol/L vs 61.4?±?23.8 ?mol/L; p?=?0.027).

Conclusions

Biochemical nutritional markers remained unchanged which is an encouraging finding in adults with PKU, many of whom are unable to maintain full adherence with nutritionally fortified protein substitutes. Longitudinal, prospective studies with larger sample sizes are necessary to fully understand the metabolic impact of using CGMP-AA in PKU.

SUBMITTER: Pena MJ 

PROVIDER: S-EPMC7881530 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective.

Pena Maria João MJ   Pinto Alex A   de Almeida Manuela Ferreira MF   de Sousa Barbosa Catarina C   Ramos Paula Cristina PC   Rocha Sara S   Guimas Arlindo A   Ribeiro Rosa R   Martins Esmeralda E   Bandeira Anabela A   Dias Cláudia Camila CC   MacDonald Anita A   Borges Nuno N   Rocha Júlio César JC  

Orphanet journal of rare diseases 20210213 1


<h4>Background</h4>In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing on the long-term nutritional status of CGMP-AA are lacking. This retrospective study evaluated the long-term impact of CGMP-AA over a mean of 29 months in 11 patients with a mean age at CGMP-AA onset of 28 years (range 15-43) [8 females; 2 hyperphenylalaninaemia (HPA),  ...[more]

Similar Datasets

| S-EPMC4962165 | biostudies-literature
| S-EPMC6266274 | biostudies-other
| S-EPMC11013192 | biostudies-literature
| S-EPMC7576483 | biostudies-literature
| S-EPMC4004170 | biostudies-literature
| S-EPMC6377744 | biostudies-literature
| S-EPMC5804357 | biostudies-literature
| S-EPMC4789337 | biostudies-literature
| S-EPMC10459832 | biostudies-literature
| S-EPMC3402906 | biostudies-literature